Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Long-Term Investments: 2010-2023

Historic Long-Term Investments for Myriad Genetics (MYGN) over the last 12 years, with Jun 2023 value amounting to $6.2 million.

  • Myriad Genetics' Long-Term Investments fell 92.10% to $6.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $6.2 million, marking a year-over-year decrease of 92.10%. This contributed to the annual value of $54.8 million for FY2022, which is 7.12% down from last year.
  • Myriad Genetics' Long-Term Investments amounted to $6.2 million in Q2 2023, which was down 79.61% from $30.4 million recorded in Q1 2023.
  • Myriad Genetics' Long-Term Investments' 5-year high stood at $78.5 million during Q2 2022, with a 5-year trough of $6.2 million in Q2 2023.
  • Its 3-year average for Long-Term Investments is $44.5 million, with a median of $51.1 million in 2021.
  • In the last 5 years, Myriad Genetics' Long-Term Investments soared by 494.96% in 2022 and then crashed by 92.10% in 2023.
  • Myriad Genetics' Long-Term Investments (Quarterly) stood at $47.6 million in 2019, then slumped by 55.88% to $21.0 million in 2020, then spiked by 180.95% to $59.0 million in 2021, then decreased by 7.12% to $54.8 million in 2022, then plummeted by 92.10% to $6.2 million in 2023.
  • Its last three reported values are $6.2 million in Q2 2023, $30.4 million for Q1 2023, and $54.8 million during Q4 2022.